Skip to main content

Table 2 Univariate and multivariate analyses of disease-free survival for initial HR-positive patients with adjuvant endocrinotherapy after surgery

From: Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy

Characteristics N (%) DFS
Uv Mv
P HR (95% CI) P HR (95% CI)
Age, years   0.181    
 ≤ 50 146 (68.5)   1.00   
 > 50 67 (31.5)   0.645 (0.340–1.226)   
Initial tumor stage   0.649    
 T1 38 (17.8)   1.00   
 T2 107 (50.2) 0.364 1.436 (0.658–3.136)   
 T3 or T4 68 (31.9) 0.428 1.413 (0.601–3.321)   
Initial node status   0.037   0.481  
 Negative 26 (12.2)   1.00   1.00
 Positive 187 (87.8)   4.506 (1.093–18.570)   1.839 (0.338–9.992)
Nuclear grade   0.246    
 1 or 2 73 (34.3)   1.00   
 3 55 (25.8)   1.475 (0.765–2.845)   
 NA 85 (39.9)   
Histology   0.877    
 IDC 183 (85.9)   1.00   
 Mixed 17 (8.0) 0.802 1.126 (0.446–2.841)   
 Other 13 (6.1) 0.639 1.277 (0.459–3.554)   
Initial HER2 status   0.618    
 Negative 182 (85.4)   1.00   
 Positive 31 (14.5)   1.200 (0.586–2.456)   
Initial Ki-67 status   0.584    
 < 15% 57 (26.8)   1.00   
 ≥ 15% 156 (73.2)   1.191 (0.638–2.223)   
NAC regimens   0.058    
 Anthracycline-based 65 (30.5)   1.00   
 Anthracycline- and Taxane-based 133 (62.4) 0.895 0.959 (0.512–1.797)   
 Taxane-based 15 (7.0) 0.043 2.561 (1.032–6.357)   
Any receptor conversion   0.017   0.031  
 No 167 (78.4)   1.00   1.00
 Yes 46 (21.6)   1.995 (1.130–3.521)   1.881 (1.058–3.342)
Tumor size at surgery   0.694    
 ≤ 2 cm 88 (41.3)   1.00   
 > 2 and ≤ 5 cm 114 (53.5) 0.393 1.282 (0.725–2.267)   
 > 5 cm 11 (5.2) 0.806 1.165 (0.344–3.944)   
Node status at surgery   0.005   0.095  
 Negative 49 (23.0)   1.00   1.00
 Positive 164 (77.0)   3.774 (1.498–9.507)   2.556 (0.846–7.698)
HER2 status at surgery   0.587    
 Negative 184 (86.4)   1.00   
 Positive 29 (13.6)   0.790 (0.338–1.848)   
Ki-67 status at surgery   0.405    
 < 15% 116 (54.5)   1.00   
 ≥ 15% 97 (45.5)   1.255 (0.736–2.142)   
Radiotherapy   0.031   0.329  
 No 57 (26.8)   1.00   1.00
 Yes 156 (73.2)   2.280 (1.076–4.831)   1.476 (0.675–3.227)
  1. DFS disease-free survival, HR hazard ratio, CI confidence interval, Uv univariate Cox proportional hazard analyses, Mv multivariate Cox proportional hazard analyses, IDC invasive ductal carcinoma, HER2 human epidermal growth factor receptor 2, NAC neoadjuvant chemotherapy